Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Asset Writedowns and Impairment (2020 - 2023)

Summit Therapeutics (SMMT) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $474000.0 as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Asset Writedowns and Impairment changed N/A year-over-year to $474000.0, compared with a TTM value of $474000.0 through Dec 2023, changed N/A, and an annual FY2023 reading of $474000.0, changed N/A over the prior year.
  • Asset Writedowns and Impairment was $474000.0 for Q1 2023 at Summit Therapeutics, down from $859000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $859000.0 in Q3 2020 and bottomed at $474000.0 in Q1 2023.